Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP5094 Phase 1 in RA on Methotrexate
NCT02698657Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ASP5094 Dose Escalation with Placebo Dose Escalation (2 arms). Primary endpoints: Treatment-Emergent Adverse Events, Total Lymphocyte Counts at Day 141 and 7 more. Started Feb 2016; status: completed.
02
Drugs
ASP5094
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02698657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698657.